Silence Therapeutics focused on clinical execution in 2025, notably accelerating the Phase 2 SANRECO trial for divesiran. While the company reported a significant decrease in annual collaboration revenue following the conclusion of the Hansoh partnership and reduced AstraZeneca revenue, it maintains a solid cash position of $85.1 million to fund its prioritized siRNA pipeline.

Silence Therapeutics reported a net loss of $28.5 million for Q1 2025, with revenues of $0.142 million. The company ended the quarter with $136.5 million in cash, cash equivalents, and short-term investments, and extended its cash guidance into 2028 through cost-saving initiatives.

Silence Therapeutics reported its full year 2024 financial results. The company ended the year with over $147 million in cash, cash equivalents and short-term investments and is extending its projected cash runway into 2027 by prioritizing divesiran in PV and programs in rare conditions.